Agios Pharmaceuticals (NASDAQ:AGIO) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Agios Pharmaceuticals (NASDAQ:AGIO) from a sell rating to a hold rating in a research report report published on Sunday.

A number of other equities analysts also recently commented on AGIO. Citigroup lifted their target price on Agios Pharmaceuticals from $38.00 to $46.00 and gave the company a “buy” rating in a research note on Thursday, March 5th. HC Wainwright increased their price target on Agios Pharmaceuticals from $62.00 to $65.00 and gave the stock a “buy” rating in a research report on Thursday, February 12th. Leerink Partners raised their price target on Agios Pharmaceuticals from $34.00 to $40.00 and gave the stock an “outperform” rating in a report on Friday, December 26th. JPMorgan Chase & Co. boosted their price objective on Agios Pharmaceuticals from $20.00 to $25.00 and gave the company a “neutral” rating in a research report on Tuesday, January 6th. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Agios Pharmaceuticals in a research note on Monday, December 29th. Six research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $40.67.

Agios Pharmaceuticals Stock Performance

Agios Pharmaceuticals stock opened at $28.35 on Friday. Agios Pharmaceuticals has a 1 year low of $22.24 and a 1 year high of $46.00. The firm’s 50-day moving average is $28.18 and its 200-day moving average is $32.38. The company has a market cap of $1.66 billion, a P/E ratio of -3.99 and a beta of 0.89.

Insider Transactions at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, CEO Brian Goff sold 18,703 shares of the firm’s stock in a transaction that occurred on Tuesday, December 30th. The shares were sold at an average price of $27.09, for a total value of $506,664.27. Following the sale, the chief executive officer owned 136,583 shares in the company, valued at approximately $3,700,033.47. This trade represents a 12.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Krishnan Viswanadhan sold 2,959 shares of the business’s stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $27.80, for a total value of $82,260.20. Following the transaction, the insider owned 5,141 shares of the company’s stock, valued at approximately $142,919.80. This represents a 36.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 36,262 shares of company stock worth $984,237 in the last quarter. 4.93% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of AGIO. T. Rowe Price Investment Management Inc. bought a new stake in shares of Agios Pharmaceuticals during the fourth quarter valued at about $25,000. First Horizon Corp bought a new position in Agios Pharmaceuticals in the 3rd quarter valued at about $45,000. Assetmark Inc. grew its position in Agios Pharmaceuticals by 37.9% in the 4th quarter. Assetmark Inc. now owns 1,317 shares of the biopharmaceutical company’s stock valued at $36,000 after buying an additional 362 shares in the last quarter. NewEdge Advisors LLC acquired a new position in Agios Pharmaceuticals during the 1st quarter valued at about $40,000. Finally, Caitong International Asset Management Co. Ltd bought a new stake in shares of Agios Pharmaceuticals during the 4th quarter worth about $49,000.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.